Peptide Therapies for Retinal Disease: Anti-VEGF Peptides, AMD, and Diabetic Retinopathy

The retina is the thin layer at the back of the eye. It captures light and sends signals to the brain so we can see.

When the retina is damaged, vision can be lost. This can be partial or complete blindness.

Common Retinal Diseases

Two of the most common and serious retinal diseases are:

• Age-related macular degeneration (AMD): Damage to the central part of the retina, called the macula. It is the leading cause of blindness in people over 65.
• Diabetic retinopathy (DR): Damage to blood vessels in the retina caused by high blood sugar. It affects about 1 in 3 people with diabetes.

Both diseases involve abnormal blood vessel growth and inflammation that destroy retinal cells over time.

AMD affects more than 200 million people worldwide. By 2040, that number is expected to reach 300 million as populations age.

Why Peptides Are Valuable in Retinal Disease

The retina is very complex and delicate. Treatments must be very precise.

Peptides can target specific proteins that drive retinal disease without affecting the rest of the eye or body. They can also be designed to protect nerve cells in the retina, which cannot grow back once lost.

Another advantage is size. Peptides are smaller than antibodies, which means they can reach parts of the retina that larger molecules cannot.

Anti-VEGF peptides can be as small as 1/100th the molecular weight of antibody therapies like ranibizumab, which is why researchers believe topical eye-drop delivery may eventually be feasible for wet AMD.

Anti-VEGF Peptides

VEGF (vascular endothelial growth factor) is a protein that tells the body to grow new blood vessels. In retinal diseases, too much VEGF causes abnormal blood vessels to grow in the retina.

These new vessels are weak and leaky. They damage the retina and cause vision loss.

Blocking VEGF is one of the most successful approaches in eye medicine. Current approved treatments include large protein drugs (antibodies) like ranibizumab, bevacizumab, and aflibercept.

But peptides offer a new approach. Small anti-VEGF peptides are being developed that can block VEGF more efficiently and in ways that may allow eye drops instead of injections.

Cyclic Anti-VEGF Peptides

Cyclic peptides are ring-shaped peptides that are more stable in the eye than straight-chain peptides. Several cyclic peptides that block VEGF binding to its receptor have been developed.

These include peptides derived from the VEGF-binding site of the VEGF receptor. They block the VEGF signal at the source.

KP-1 Peptide

KP-1 is an anti-VEGF peptide developed by Kala Bio. It was designed to block both VEGF-A and VEGF-B.

In early studies, it showed strong inhibition of abnormal blood vessel growth with fewer side effects than antibody-based treatments.

Multivalent Peptide Inhibitors

Some researchers are building multivalent peptides that have multiple copies of the VEGF-blocking sequence. These have much stronger activity because they bind to VEGF at more than one site at once.

Expert Quote: "Small anti-VEGF peptides could transform retinal disease treatment if they enable effective topical delivery. The vision of an eye drop instead of an injection is a powerful motivator for this research." - Dr. David Bhisitkul, University of California San Francisco

Neuroprotective Retinal Peptides

Protecting the nerve cells of the retina (called retinal ganglion cells and photoreceptors) is another major goal. Once these cells die, vision loss is permanent.

Neuroprotective peptides aim to keep retinal neurons alive even in the face of disease and damage.

PEDF (Pigment Epithelium-Derived Factor)

PEDF is a natural protein with strong neuroprotective and anti-angiogenic properties. Small peptides derived from PEDF have been developed that keep these protective effects.

A 17-amino acid PEDF peptide (PEDF-34) has been shown to protect retinal cells from death in several animal models of retinal degeneration.

Humanin

Humanin is a short peptide that protects cells from programmed cell death (apoptosis). It was discovered in mitochondrial DNA.

Humanin and its analogs (like HNGF6A) have shown strong protection of retinal cells in models of AMD and diabetic retinopathy. They reduce oxidative stress and cellular damage.

NAP (NAPVSIPQ)

NAP is an 8-amino acid peptide derived from the neuroprotective protein ADNP (activity-dependent neuroprotective protein). It has been shown to protect multiple types of nerve cells.

In retinal disease models, NAP reduced inflammation and cell death. It is one of the most studied neuroprotective peptides across multiple neurological and ocular conditions.

Peptide Targets and Stages in Retinal Disease Research

Peptide	Target	Disease	Route	Development Stage
Cyclic anti-VEGF peptides	VEGF receptor	AMD, DR	Intravitreal	Preclinical
PEDF-34	Neuroprotection/anti-VEGF	AMD, retinal degeneration	Intravitreal	Preclinical
Humanin analogs	Apoptosis inhibition	AMD, DR	Systemic/topical	Preclinical
NAP peptide	ADNP neuroprotection	Retinal degeneration	Topical/nasal	Phase 2 (CNS)
RGD integrin peptides	Cell adhesion/survival	DR	Topical	Preclinical
Substance P fragments	Neural repair	Retinal injury	Intravitreal	Preclinical

When hiring for retinal peptide programs, prioritize candidates with dual expertise in ocular pharmacokinetics and peptide cyclization chemistry, as cyclic peptide stability in the vitreous humor is a core bottleneck that generalist peptide chemists often underestimate.

Peptides for Diabetic Retinopathy

Diabetic retinopathy (DR) involves several processes: blood vessel leakage, inflammation, and nerve damage. Peptides that address multiple aspects of DR are especially needed. For authoritative context, see the NIH National Eye Institute.

C-Peptide

C-peptide is a part of insulin that was long thought to be inactive. Research has shown it protects small blood vessels and nerves from diabetes damage.

In early clinical studies, C-peptide reduced the loss of small blood vessels in the retinas of diabetic patients. It also showed nerve-protective effects.

Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

GLP-1 agonists like semaglutide reduce the risk of diabetic retinopathy worsening in people with type 2 diabetes. They work by reducing overall blood sugar and inflammation.

Studies show that semaglutide users have a lower rate of DR progression. Research into how GLP-1 receptor activation directly protects retinal vessels is ongoing.

Ocular Drug Delivery for Peptides

Getting peptides to the retina is one of the biggest challenges in eye medicine. The eye is protected by several barriers.

The main routes being explored are:

Route	Description	Advantage	Challenge
Intravitreal injection	Injected directly into the eye	Best delivery to retina	Uncomfortable, risk of infection
Topical eye drops	Applied to the eye surface	Easy and painless	Hard to reach retina
Subretinal injection	Injected under the retina	Very precise delivery	Complex procedure
Periocular injection	Around the eye	Less invasive	Variable delivery
Systemic (IV/oral)	Through the bloodstream	No eye procedure	Eye barriers filter out most peptides

Cell-penetrating peptides are being used as carriers to help other peptides cross the eye barriers. Nanoparticle encapsulation is another key strategy.

Current anti-VEGF injections for AMD require up to 12 injections per year. Many patients stop treatment because of the frequency and discomfort. A more patient-friendly peptide eye drop could greatly improve outcomes.

Peptides in Dry AMD

Dry AMD (also called geographic atrophy) is the more common form of AMD. There are very few treatments for it.

Peptides that protect the retinal pigment epithelium (RPE) cells from dying are a major research focus for dry AMD. The C3 complement pathway is overactive in dry AMD, and peptide inhibitors of this pathway are being tested.

APL-2 (pegcetacoplan), a cyclic peptide that blocks complement factor C3, has received FDA approval for geographic atrophy. This is a major milestone for peptide drugs in retinal disease.

Anti-VEGF peptides and neuroprotective compounds like PEDF represent a meaningful shift in retinal disease treatment, moving from repeated antibody injections toward smaller, more deliverable molecules that could one day reach patients through eye drops rather than needles.

FAQs

What is the role of anti-VEGF peptides in treating AMD?

Anti-VEGF peptides block VEGF, a protein that causes abnormal blood vessel growth in the retina. Too many leaky blood vessels damage the macula and cause vision loss. Peptides that block VEGF can stop or slow this process. Smaller peptides may eventually enable eye drop delivery instead of injections.

Are there FDA-approved peptide drugs for retinal disease?

Yes. APL-2 (pegcetacoplan), a cyclic peptide inhibitor of complement C3, was approved by the FDA for geographic atrophy (dry AMD). GLP-1 receptor agonist peptides like semaglutide also reduce the risk of diabetic retinopathy progression in diabetic patients.

How do neuroprotective peptides help the retina?

Neuroprotective peptides protect the nerve cells of the retina from dying. They reduce oxidative stress, block programmed cell death, and support cell survival signals. Retinal nerve cells cannot regenerate, so protecting them is critical to preserving vision.

What is diabetic retinopathy and how can peptides help?

Diabetic retinopathy is damage to the retinal blood vessels caused by high blood sugar. Peptides can help by protecting these vessels, reducing inflammation, improving blood sugar control, and protecting nerve cells from damage. C-peptide and GLP-1 agonists are among the most studied options.

What are the challenges of delivering peptides to the retina?

The eye has several protective barriers that keep foreign substances out. Getting peptides to the retina in large enough amounts is difficult without injection. Researchers are developing nanoparticles, cell-penetrating carriers, and improved topical formulations to make non-invasive delivery possible.

Find Top Retinal Disease Peptide Researchers With PeptideStaff

Developing peptide therapies for retinal diseases requires rare expertise across ocular biology, peptide chemistry, drug delivery, and clinical trials. These specialists are in high demand.

PeptideStaff connects life science organizations with the expert peptide researchers and development professionals they need.

Contact PeptideStaff today to staff your retinal disease peptide research program.